Background/Aims: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease, and is the most common type of lymphoma in adults. Although significant progress in treatment has been made using chemotherapy combinations, there exist a large amount of relapse or refractory cases. Thus, effective clinical biomarkers for DLBCL are urgently needed. Our study aims to explore the predictive significance of using the immune response to tumor burden ratio [defined as the lymphocyte to monocyte ratio (LMR)/lactate dehydrogenase (LDH) levels] in 184 DLBCL patients and the potential mechanism underlying the use of the LMR to tumor burden ratio in predicting patient survival. Methods: The correlation between serum LDH levels and tumor levels assessed by PET-CT was determined using Spearman's correlation analysis. Clinical data from 184 DLBCL patients was assessed using receiver operating characteristic curve analysis and survival analysis. The potential correlation between tumor burden and lymphocytes or monocytes was analyzed by immunohistochemical staining, flow cytometry, and ELISA analysis of patient samples. In addition, we performed in vitro studies to further determine the effects of tumor burden on the anti-tumor activity of T lymphocytes. Results: We observed that serum LDH was an excellent surrogate marker of tumor burden in DLBCL patients, and that the ratio of LMR to LDH was an independent prognostic biomarker capable of predicting survival in DLBCL patients. Further analysis showed that a high tumor burden was correlated with decreased Ki67 expression in T cells, either in the solid tumor tissue or in the circulating blood. In addition, based on an in vitro co-culture study, a higher
Introduction
Non-Hodgkin's lymphomas (NHLs) are a diverse group of diseases originating from lymphoid tissues, consisting of considerable subtypes with heterogeneous biological characteristics and clinical behaviors [1, 2] . Diffuse large B-cell lymphoma (DLBCL), which is the most common type of NHL, is characterized by an aggressive natural history of untreated patients, with a median survival of less than one year [3, 4] . Despite the remarkable success of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy, or rituximab plus CHOP (R-CHOP) chemotherapy, approximately 30% of DLBCL patients suffer relapse or refractory disease [3] [4] [5] [6] . Therefore, the identification of effective biomarkers should be helpful in improving the clinical prognosis in DLBCL patients.
Recent breakthroughs in immunotherapy have attracted a broad interest for treating tumor in an effective way [7, 8] . Numerous clinical studies have focused on improving survival outcomes using novel combinations of immunotherapy and chemotherapy in DLBCL patients [9, 10] . Thus, effective immunological biomarkers should be considered when evaluating the immune status of the patients. In this regard, the prognostic value of the lymphocyte to monocyte ratio (LMR), which mirrors the circulating immune status of the host, has been reported for a number of different malignancies [11] [12] [13] . In particular, LMR has been suggested as an effective prognostic factor for predicting clinical survival in DLBCL patients [14, 15] . However, a recent study has suggested that an immunological biomarker alone is not sufficient to predict survival and clinical responses, and the immune cell invigoration to tumor burden ratio could be useful as an indicator of clinical response [16] .
Tumor burden is thought to be an important risk factor in multiple malignancies, usually reflecting the degree of tumor damage to the body [17, 18] . In solid tumors, such as melanoma, breast cancer, and lung cancer, tumor burden is always represented as the tumor size assessed using a CT scan [17] . However, as a hematopoietic and lymphoid disease, CT scan is not always performed to assess the tumor burden in DLBCL due to the large number of lymph nodes involved, as well as tumors in extra-nodal tissues. Although FDG-PET/CT is more accurate in identifying lesions than a CT scan, its use has been limited because of its cost [19, 20] . Lactate dehydrogenase (LDH) has been recognized to be a potential circulating surrogate for the tumor burden; it is inexpensive and can easily be assessed clinically [16, 21] . Therefore, in the present study, we investigated whether LDH was able to reflect the tumor burden in DLBCL patients, and performed a retrospective analysis to determine the prognostic value of the LMR to tumor burden ratio and the potential mechanism underlying this ratio to allow for its future application in DLBCL.
Materials and Methods

Patient selection
In this retrospective study, we reviewed a database of 184 patients from East Asia who were diagnosed as denovo DLBCL patients. All the patients were selected from January 2008 to December 2012 from the Harbin Medical University Cancer Hospital and met the inclusion criteria, including pathological confirmation of DLBCL, no previous treatment, and no prior history of other malignancies. All patients were treated with CHOP or R-CHOP chemotherapy regimens, with or without involved-field radiation therapy. This study protocol was performed in accordance with the principles of the Declaration of Helsinki, and approved by the Institutional Review Board of Harbin Medical University Cancer Hospital. Written informed consent was obtained from every participant, and informed consent from patients less than 16 years old was obtained from their guardians. All methods were performed in accordance with the relevant guidelines and regulations.
Laboratory data
Absolute lymphocyte and monocyte counts were obtained from the peripheral blood samples of DLBCL patients before treatment, and standard complete blood cell count (CBC) data were obtained using a Sysmex XT-1800 Automated Hematology System (Shanghai, China). Each LMR was calculated by dividing the lymphocyte count by the monocyte count. Serum LDH levels were measured with an Olympus® AU640 clinical chemistry analyzer. We defined "R" to represent the LMR to LDH ratio as R = LMR/LDH×100 (%).
FDG-PET/CT scanning
Whole-body 18 F-FDG PET/CT studies were performed before the start of treatment. After a 6-hour fasting period, the patients were intravenously injected with approximately 4-5 MBq/kg body weight of 18 F-FDG. Following this, at 60 minutes post 18 F-FDG injection, the patients were scanned from the skull base to the knees.PET scanning was performed in the same position in the 2-dimensional mode (4 minutes per bed position, and 6-7 bed positions for the emission scans). CT scanning was performed at 120 kV and 30 mA for the attenuation correction of the FDG signal. The FOV and pixel size of PET images were analyzed using a computer workstation (Xeleris; General Electric Medical System).
Immunohistochemical (IHC) staining
The IHC staining was performed to detect the expression of Ki67 and CD163 in tumor tissue sections. Briefly, slides were dried overnight at 60°C followed by de-paraffinized in xylene and rehydrated through graded ethanol. Next, antigens were retrieved using citrate buffer (pH 6.0) by microwaves and then incubated with 3% H 2 O 2 in methanol for 10 minutes to quench endogenous peroxidase activity. Subsequently, the sections were incubated with 5% bovine serum albumin for 30 minutes and then incubated with primary antibody [anti-Ki67 antibody (dilution 1:200; ab15580, Abcam, Cambridge, USA); anti-CD163 antibody (dilution 1:300; ab182422, Abcam, Cambridge, USA)] at 4°C overnight. Later, the sections were incubated with HRP-labelled goat anti-rat secondary antibody (ab97057, Abcam, Cambridge, USA) for 20 minutes at 37°C. Then the slides were counterstained with instant hematoxylin, and then dehydrated, cleared, and mounted. For the negative control, phosphate buffered saline was used instead of the primary antibody.
Cell preparation
Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation using Ficoll-Hypaque (GE HealthCare, Helsinki, Finland) according to the manufacturer's protocols. T-cells were separated from the PBMCs and expanded using an interleukin-2 (IL-2)-containing culture media. The human diffuse large B cell line, SU-DHL-6, was purchased from the China Center for Type Culture Collection (Wuhan, China). All the cells were incubated in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics (10000U/mL penicillin and 10μg/mL streptomycin) and maintained in a humidified incubator at 37°C with 5% CO 2 .
Flow cytometry
CD8
+ T cells were isolated from PBMCs using Manual MACS Cell Separation (Miltenyi Biotech; Auburn, CA, USA). Sorted cells were stained with a FITC-labeled anti-CD8antibody (RPA-T8, ebioscience, San Diego, CA, USA), and then fixed with 4% fixation buffer for 10 minutes. Following this, cells were washed with staining buffer and re-suspended in 100 μL of permeabilization buffer (BD Biosciences, San Diego, CA, USA) and incubated for 15 minutes. After the cells were washed with staining buffer, Ki-67-PE (20Raj1, ebioscience, San Diego, CA, USA) was added and incubated at 4°C for 30 minutes. Finally, the stained cells were re-suspended in 100 μL of 1% fixation buffer and analyzed using a BD Biosciences LSRFortessa, and the data obtained was analyzed using BD Accuri C6 software (FlowJo, San Jose, CA, USA).
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Cellular Physiology and Biochemistry The T cells, expanded as described above, were co-cultured with1 × 10 5 SU-DHL-6 cells [pre-treated with mitomycin C (10μg/mL) for 2hours] at T cell/tumor cell culture ratios of 20:1, 10:1, 5:1, and 1:1. SU-DHL-6 cells were sorted from the co-culture system by fluorescence activated cell sorting (FACS) using flow cytometry at 0, 24, 48, and 60 hours, respectively. The cells were stained with an FITC-labeled antiCD20antibody (BD Bioscience, San Diego, CA, USA), and then analyzed using an FACS Calibur 1 (Becton Dickinson, San Jose, CA, USA). Finally, the cells were evaluated by cell counting using a TM10™ automated cell counter (Bio-Rad Laboratories, Hercules, CA, USA).
Real-time PCR
Total mRNA was extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was generated using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics). Realtime RT-PCR for granzyme B (forward primer5′-TCCTAAGAACTTCTCCAACGACATC-3′, reverse primer 5′-GCACAGCTCTGGTCCGCT-3′) was performed using SYBR Premix Ex Taq II (TaKaRa, Ohtsu, Japan). The relative quantification of mRNA expression was calculated by the 2 -ΔΔCt method.
Enzyme-linked immunosorbent assay (ELISA)
Peripheral blood serum samples (for CCL3 and IL-10 levels) and cell supernatants(for IFN-γ levels) were analyzed using the appropriate Quantikine Kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. The absorbance was determined at a wavelength of 450nm using a Bio-Rad Model 680 Microplate Reader (BioRad Laboratories, Tokyo, Japan).
Statistical analysis
A Spearman correlation analysis was performed to determine the correlation between serum LDH and the maximum standardized uptake value (SUVmax) measured using FDG-PET/CT. The best cut-off points for LMR and R were determined using a receiver operating characteristics (ROC) curve analysis, and were considered as having the highest Youden index (sensitivity + specificity-1). The significance of associations between groups with clinicopathological variables was determined using Chi-squared and Fisher's Exact tests. Overall survival (OS) was defined as the time from the date of diagnosis until death from any cause, or the last follow-up. Progression-free survival (PFS) was calculated from the day of treatment until relapse, disease progression, death from any cause, or the last follow-up. OS and PFS curves were determined using the Kaplan-Meier method, and were compared using the log-rank test. Multivariate modeling was assessed using a Cox regression analysis. IHC, flow cytometry, RT-PCR, and ELISA data were analyzed and are shown as mean ± standard deviation (SD). P < 0.05 was considered as being statistically significant. All statistical analyses were performed using IBM SPSS 20.0 statistics software (IBM, Armonk, NY, USA). Table 1 shows the clinical data from the 184 DLBCL patients enrolled in this study. There were 106 (57.61%) males and 78 (42.39%) females, with a mean age of 54.0 (range from 13.0 to 82.0) years. The majority of the patients (120 cases, 65.22%) had localized disease (Ann Arbor stage I-II). Based on the Eastern Cooperative Oncology Group performance status (ECOG PS), 149 (80.98%) patients were in group 0-1. In addition, 49 (26.63%) patients had positive B symptoms, and more than one-half of the patients (108 cases, 58.69%) were in the low risk group. At diagnosis, the median LDH was 230.79 U/L (range from 70-1026 U/L).
Results
Clinical characteristics of 184 patients with DLBCL
Serum LDH levels reflect tumor burden
To evaluate whether the serum LDH level is able to reflect the tumor burden in DLBCL patients, we performed a Spearman correlation analysis evaluating the relationship between serum LDH and SUVmax for all lesions measured by FDG-PET/CT in patients. The data shown in Fig. 1a indicated a significantly positive correlation between serum LDH levels and FDG uptake based on PET/CT (P < 0.01), with a correlation coefficient of 0.78. Using the ROC curve, we selected the best cut-off value for LDH levels in order to divide the patients 
LMR/LDH ratio shows a higher significant correlation with the clinical characteristics of DLBCL patients than LMR
The ROC curves were also generated to select the appropriate cut-off values of LMR and the LMR/ LDH ratio based on the survival analysis. For LMR, the AUC was 0.616 (95% CI: 0.516-0.717, P = 0.027) in all patients (Fig.  1c) , with an LMR value of 3.14. With respect to the LMR/LDH ratio, the AUC was calculated to be 0.694 (95% CI: 0.601-0.787, P < 0.001) in patients (Fig. 1d) , with an LMR/LDH value of 1.26. The relationships between LMR or LMR/LDH and baseline clinical features are listed in Table 1 . Patients with an LMR ≤ 3.14 had a higher incidence of advanced Ann Arbor stage (P = 0.031), ECOG PS (P = 0.034), B symptoms (P = 0.042), and elevated LDH level (P = 0.008); however, the IPI score was not statistically significant (P = 0.054). For the LMR/LDH ratio, this was more significantly related to the Ann Arbor stage (P = 0.002), ECOG PS (P = 0.008), B symptoms (P = 0.003), IPI score (P = 0.002), as well as the LDH level (P < 0.001). 
LMR/LDH ratio demonstrates a greater prognostic significance in DLBCL patients
Kaplan-Meier curves were generated to evaluate the OS and PFS rates based on LMR and LMR/LDH, as shown in Fig. 2 . Patients with LMR ≤ 3.14 had significantly lower OS (P = 0.024; Fig. 2a ) and PFS (P = 0.002; Fig. 2b ) compared to those with LMR > 3.14. With respect to the LMR/LDH ratio, the survival curves showed more prognostic significance; patients with R ≤ 1.26 had much lower OS (P < 0.001; Fig. 2c ) and PFS (P < 0.001; Fig. 2d )comparing with values R > 1.26.
LMR/LDH ratio is an independent prognostic marker in DLBCL patients
We used a Cox Regression model to evaluate the prognostic impact of the LMR/LDH ratio at diagnosis on the survival of DLBCL patients. In the multivariate analysis, the LMR/LDH ratio was identified as being an independent prognostic marker for OS (P = 0.037, HR = 2.543; 95%CI: 1.056-6.125) and PFS (P = 0.018, HR = 2.807; 95%CI: 1.196-6.589); however, the results were not significant for LMR or LDH alone, either in OS (P = 0.605, P = 0.142) or PFS (P = 0.965, P = 0.654). Moreover, OS and PFS were also significantly associated with age (P = Table 2) .
Tumor burden correlates with T cell proliferation
We then assessed whether tumor burden was correlated with T cell proliferation in DLBCL patients. Ki67 is a marker of T cell proliferation in tumor masses, as well as in peripheral blood samples. Thus we analyzed changes in Ki67 expression in CD8 + T cells in patients with different tumor burdens as shown by high or low LDH levels. Tissue samples from patients with low LDH levels showed a positive expression of Ki67 in the tumor infiltrating lymphocytes (TILs), whereas in patients in the high LDH group, Ki67 expression was almost absent (Fig. 3a) . From the flow cytometry analysis, Ki67 expression in the CD8 + T cells persisted at low levels in DLBCL patients with higher LDH levels. In contrast, Ki67 expression was remarkably increased in patients with low LDH levels (P < 0.001, Fig 3c and  3d) , suggesting a negative correlation between T cell proliferation and tumor burden in peripheral blood samples of DLBCL patients. 
A higher tumor burden decreases the anti-tumor effects of T lymphocytes
To further evaluate whether tumor burden would affect the anti-tumor function of T lymphocytes, we co-cultured T cells with SU-DHL-6 cells at different T cell/tumor cell ratios of 20:1, 10:1, 5:1 and 1:1. Fig. 4a shows the number of SU-DHL-6 cells following incubation with different amounts of T cells for 0, 24, 48, and 60 hours. We found a significant decrease in the SU-DHL-6 cell count at lower tumor burden ratios (T cell/tumor cell ratio of 20:1) compared to higher tumor burden ratios (T cell / tumor cell ratio of 1:1) (P = 0.003 and P = 0.002 respectively). In addition, the expression of granzyme B in T cells and IFN-γ in cell supernatants in the coculture with a 1:1 T cell/tumor cell ratio was significantly lower than in the coculture with a 20:1 T cell/tumor cell ratio (P < 0.001, Fig. 4b ; P = 0.006, Fig.  4c ). Taken together, these observations suggest a weaker anti-tumor effect of the T cells at higher tumor burdens.
Higher tumor burden contributes to the differentiation of monocytes to tumor associated macrophages (TAMs)
It has been demonstrated that peripheral blood monocytes can be recruited to tumors and differentiated into TAMs in response to the chemokines or cytokines released by the tumor cells. Thus, we examined the serum levels of CCL3 and IL-10 expression in DLBCL patients by ELISA analysis and examined the differentiation of monocytes into TAMs. The data showed that the serum CCL3 and IL-10 levels were significantly increased in patients with high LDH levels (P = 0.002, Fig. 5a; P = 0.03, Fig. 5b ). In parallel, we detected Cellular Physiology and Biochemistry
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higher expression levels of CD163 in tissue samples from patients with high LDH levels ( Fig.  5c) , which suggests that a higher tumor burden is able to promote the differentiation of monocytes to TAMs.
Discussion
In this study, we report the predictive significance of the LMR to tumor burden ratio (LMR/LDH) in 184 DLBCL patients and investigated the potential correlation of tumor burden with immune system status. There were several findings relevant to the understanding of the LMR/LDH ratio in predicting clinical outcomes more significantly. To our knowledge, this is the first large-scale study to evaluate the prognostic value of the LMR/LDH ratio in DLBCL patients. Our study demonstrated the utility of using this novel predictive biomarker, which assesses both the immune system and tumor burden, in DLBCL patients, thus opening avenues for future mechanistic exploration.
Recently, the lymphocyte to monocyte ratio has been reported to be an important prognostic indicator for many malignancies, including DLBCL [11] [12] [13] [14] [15] . The levels of circulating lymphocytes and monocytes are reflective of both the immunological function in the peripheral blood as well as in the tumor micro-environment [22, 23] . Lymphocytes have an important anti-tumor role in tumor immunity, and a low lymphocyte level might weaken the host immunological response to malignancy [24] . In contrast, monocytes are considered to be negative factors for malignancy as they may infiltrate into tumor sites and differentiate into TAMs, which can promote angiogenesis, tumor proliferation, and metastasis by releasing growth factors and immune-suppressive cytokines [25, 26] . Thus, the lymphocyte-monocyte ratio reflects the immune status of the host, but more importantly, it might be able to predict the survival outcomes of patients with malignancies, as has been reported in several studies [11] [12] [13] [14] [15] . However, there are several limitations in using only LMR to determine patient prognosis: first of all, the survival outcomes of patients are not only influenced by the immune system, but also by some tumors' intrinsic characteristics, such as the precise genetic mutation, type of pathology, and tumor size [27, 28] ; second, treatment with either chemotherapy or radiation therapy will affect the function of immune cells [29] [30] [31] ; last, but not the least, the levels and functions of lymphocytes or monocytes can be regulated by tumor cells [32] . Therefore, LMR alone is probably not a perfect predictor of the clinical survival of patients, and consideration of the tumor burden might be more valuable [16] .
Unlike other solid malignancies, DLBCL is a hematopoietic and lymphoid disease, which has a wide distribution in lymph nodes and extra-nodal tissues. PET/CT is recognized as being the most sensitive and specific imaging modality used to determine tumor burden in DLBCL patients [19, 20, 33] . However, the use of PET/CT scans in patients is often very limited before treatment. In our study, we found that serum LDH levels were significantly related to the SUVmax in PET/CT scans in DLBCL patients, which is consistent with a previous study that evaluated LDH as a potential circulating proxy for tumor burden [16] . Thus, we developed the ratio of LMR to LDH [defined as "R" = LMR/LDH ×100 (%)] in order to examine the influence of both the peripheral immune response and tumor burden on survival outcomes in DLBCL patients. Comparing the LMR/LDH ratio with LMR alone, we found that the LMR/ LDH ratio was more significantly correlated with clinical characteristics, and showed more prognostic significance for OS and PFS in the 184 DLBCL patients evaluated in this study. In addition, a multivariate analysis demonstrated that the LMR/LDH ratio was an independent prognostic biomarker, compared to LMR or LDH alone. These data suggest that the ratio of LMR to tumor burden could be a better prognostic indicator in DLBCL patients compared to LMR alone.
Moreover, we investigated the potential mechanism behind using the LMR/LDH ratio in patients with DLBCL. It is well known that Ki67 is a biomarker of cellular proliferation in tumors, and is associated with poor prognosis [34, 35] . In T lymphocytes, Ki67 expression is Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry also a good indicator of T cell activation and reinvigoration [16] . Here, we examined changes in Ki67 expression in TILs, as well as in peripheral CD8 + T cells to assess T cell responses to different tumor burdens. Our data showed that a larger tumor burden was correlated with decreased Ki67 expression in T cells, in either the solid tumor or in the circulating blood. Meanwhile, based on the data from the tumor cell/T cell co-culture system, we found that the anti-tumor responses of T cells were suppressed at high tumor burdens. In contrast, a lower tumor burden was correlated with enhanced anti-tumor effects of T cells. In addition, we found that tumor burden was associated with the generation of TAMs in the tumor microenvironment. We detected higher expression levels of CCL3, IL-10, and CD163 in patients with high LDH, indicating that a higher tumor burden induces the release of large amounts of chemokines and cytokines, which promote the recruitment of monocytes and their differentiation into TAMs, eventually leading to an immune suppressive environment in the tumor. On the basis of these observations, it might be possible to understand the role of the tumor burden on the immune system, and furthermore they raise the possibility of using the LMR to tumor burden ratio to predict survival. The relationship between LMR and tumor burden incorporates the relative balance between immune response and tumor burden. That is, if the tumor burden is high, a robust immune response might be clinically effective. Thus, it will be important to test both the immune factors and the tumor burden to define valuable predictors.
Conclusion
In conclusion, our study has identified a novel clinical biomarker, the LMR/LDH ratio, that can be used to distinguish survival outcome in DLBCL patients, and demonstrated the potential mechanism behind the successful use of the immune system combined with tumor burden. More studies are required to further understand the mechanisms underlying the use of the LMR to tumor burden ratio to facilitate its use in future clinical applications.
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